Saturday, February 28, 2015 1:55:01 PM
I can't hear you. lol
Seriously, I added another 10,000 shares to my position a couple days ago, moving me up to around 218,000 shares. I added those last 110,000 shares after reading up on Kasset Ranji.
I asked myself: "Self, why would this man invest so much money into a company that produces hospitals in rural areas?"
Answer: Pharmaceutical sales
Dr. Ranji owns various pharmacies, and he also is an angel investor in a company called NutraPharm, which has seen better days in terms of stock price.
So, here is my thesis (crazy as it might sound):
Vince Leitao (himself an Indian and a successful pharmaceutical manufacturer) strikes up a conversation with Dr. Ranji regarding the stifling regulatory procedures in Canada. Then, they strat talking about the endless possibilities in the 3rd world if only there was a hospital infrastructure to get drugs to the people. And, as an added benefit, we could likely introduce homeopathic medicines to governments more receptive to non-traditional medicine and track success rates in patients. But, without an infrastructure, especially a patient record keeping system, there would be no way to do this. At some point, Vince says. "You know, I know this guy named John Cecil."
So, I predict that not only will we see a medical infrastructure built up (which is good) but the added benefit will be that Kallo can
help negotiate bids for cheap, generic drugs as well as apply for new experimental ones, like, say, cobra venom.
Crazy you say?
Check out the following links and read them carefully, and let's all engage in a conversation. Personally, I think we have been valuing Kallo incorrectly based solely on its contracts, but there will be residuals--and that's where the bulk of ongoing profits will take place.
All JUST MY OPINION
Link 1: GHANA ENCOURAGES LOCAL PRODUCTION OF ANTI-SNAKE VENOM from March 26, 2014
http://asitisinghana.blogspot.com/2014/03/ghana-encourages-local-production-of.html
Link 2: Scroll down and read Dr. Kassett, Rajni Kassett and CobraMed Pharmaceuticals update as well as Exhibits 13, 14, and 6.
http://friendsoffreedominternational.org/articles.php?command=show&ID=20536
Link 3: Double-Blind study shows cobratoxin is effective for shingles and herpes, not so much for MS.
http://www.avarx.com/AvaRx/SubDomains/bucket6676835744268346941/Listings/bucket3913729684626650703/Public.Listing.display.html
Link 4: Check out the LAST Line--which is "Responding to the question Dr. Tia told the House that the Ministry has put in place measures to increase the supply of free serum to the rural areas."
http://www.ghananation.com/news/52841-government-encourages-local-medicine-manufacturers-to-go-into-production-of-anti-snake-venom.html
Link 5: Check out job description for Pharmacist-Medication Management
http://www.kalloinc.ca/careers_MedicationManager.aspx
Kallo: new target $5.00 JMHO
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM